168 related articles for article (PubMed ID: 36068937)
21. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
23. Molecular imaging in the management of thyroid cancer.
Wong KK; Dvorak RA; Marzola MC; Grassetto G; Gross MD; Rubello D
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):541-59. PubMed ID: 22019711
[TBL] [Abstract][Full Text] [Related]
24. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.
Salvatore B; Klain M; Nicolai E; D'Amico D; De Matteis G; Raddi M; Fonti R; Pellegrino T; Storto G; Cuocolo A; Pace L
Medicine (Baltimore); 2017 Oct; 96(42):e8344. PubMed ID: 29049252
[TBL] [Abstract][Full Text] [Related]
26. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.
Treglia G; Muoio B; Giovanella L; Salvatori M
Eur Arch Otorhinolaryngol; 2013 May; 270(6):1783-7. PubMed ID: 23053387
[TBL] [Abstract][Full Text] [Related]
27. Radioiodine Uptake in Incidentally Detected Neuroendocrine Tumor: Correlative Imaging With FDG PET/CT and 68 Ga-DOTATATE PET/CT.
Hod N; Lantsberg S; Levin D
Clin Nucl Med; 2022 Oct; 47(10):e643-e646. PubMed ID: 35485856
[TBL] [Abstract][Full Text] [Related]
28. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
29. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
30. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?
Hall NC; Kloos RT
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):793-805. PubMed ID: 17891243
[TBL] [Abstract][Full Text] [Related]
31. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostics and treatment of differentiated thyroid cancer using nuclear medicine].
Morsing A; Bogsrud TV
Ugeskr Laeger; 2012 Jun; 174(26):1813-6. PubMed ID: 22735115
[TBL] [Abstract][Full Text] [Related]
33. PET imaging for thyroid cancers: Current status and future directions.
Giraudet AL; Taïeb D
Ann Endocrinol (Paris); 2017 Feb; 78(1):38-42. PubMed ID: 27989550
[TBL] [Abstract][Full Text] [Related]
34. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic significance of MRI versus CT using identical PET data in patients with recurrent differentiated thyroid cancer: A PET/MRI study.
Westphal K; Eiber M; Henninger M; Scheidhauer K; Beer AJ; Thaiss W; Rischpler C
Medicine (Baltimore); 2023 Apr; 102(16):e33533. PubMed ID: 37083773
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
40. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
